We’re working on real solutions to rare challenges.

Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA.

DSC_0095

Our talented scientists are passionate about what matters most—people. It’s what motivates the Idera team, and it’s why we’re laser-focused on translating our pioneering nucleic acid science and technologies into medicines that will target diseases unlike any other treatment available.

  • Our Team

    Meet the team that’s dedicated to finding the next breakthrough for patients in need.